Trial Profile
An Open-Label, Single-Dose, Parallel-Group Study Of The Pharmacokinetics And Safety Of Bosutinib In Subjects With Renal Impairment And Matched Healthy Adults
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 31 Oct 2014
Price :
$35
*
At a glance
- Drugs Bosutinib (Primary)
- Indications Autosomal dominant polycystic kidney disease; Chronic myeloid leukaemia
- Focus Pharmacokinetics
- Sponsors Pfizer
- 31 Oct 2014 New trial record